AVIR
Price
$2.88
Change
-$0.02 (-0.69%)
Updated
Apr 4, 11:05 AM (EDT)
Capitalization
246.31M
33 days until earnings call
XOMA
Price
$19.24
Change
-$0.57 (-2.88%)
Updated
Apr 4, 10:30 AM (EDT)
Capitalization
237.3M
39 days until earnings call
Ad is loading...

AVIR vs XOMA

Header iconAVIR vs XOMA Comparison
Open Charts AVIR vs XOMABanner chart's image
Atea Pharmaceuticals
Price$2.88
Change-$0.02 (-0.69%)
Volume$1.89K
Capitalization246.31M
XOMA Royalty
Price$19.24
Change-$0.57 (-2.88%)
VolumeN/A
Capitalization237.3M
AVIR vs XOMA Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. XOMA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and XOMA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AVIR: $2.90 vs. XOMA: $19.81)
Brand notoriety: AVIR and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 93% vs. XOMA: 147%
Market capitalization -- AVIR: $246.31M vs. XOMA: $237.3M
AVIR [@Biotechnology] is valued at $246.31M. XOMA’s [@Biotechnology] market capitalization is $237.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AVIR and XOMA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 3 TA indicator(s) are bullish while XOMA’s TA Score has 5 bullish TA indicator(s).

  • AVIR’s TA Score: 3 bullish, 6 bearish.
  • XOMA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XOMA is a better buy in the short-term than AVIR.

Price Growth

AVIR (@Biotechnology) experienced а -3.97% price change this week, while XOMA (@Biotechnology) price change was -5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.49%. For the same industry, the average monthly price growth was -15.37%, and the average quarterly price growth was -17.15%.

Reported Earning Dates

AVIR is expected to report earnings on May 07, 2025.

XOMA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-9.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVIR($246M) and XOMA($237M) have the same market capitalization . AVIR YTD gains are higher at: -13.433 vs. XOMA (-24.619). XOMA has higher annual earnings (EBITDA): -18.71M vs. AVIR (-192.53M). AVIR has more cash in the bank: 455M vs. XOMA (143M). AVIR has less debt than XOMA: AVIR (1.64M) vs XOMA (119M). XOMA has higher revenues than AVIR: XOMA (9.71M) vs AVIR (0).
AVIRXOMAAVIR / XOMA
Capitalization246M237M104%
EBITDA-192.53M-18.71M1,029%
Gain YTD-13.433-24.61955%
P/E RatioN/AN/A-
Revenue09.71M-
Total Cash455M143M318%
Total Debt1.64M119M1%
FUNDAMENTALS RATINGS
AVIR vs XOMA: Fundamental Ratings
AVIR
XOMA
OUTLOOK RATING
1..100
7420
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
7683
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (1) in the Biotechnology industry is somewhat better than the same rating for AVIR (46). This means that XOMA’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as XOMA (100). This means that AVIR’s stock grew similarly to XOMA’s over the last 12 months.

AVIR's SMR Rating (96) in the Biotechnology industry is in the same range as XOMA (97). This means that AVIR’s stock grew similarly to XOMA’s over the last 12 months.

AVIR's Price Growth Rating (76) in the Biotechnology industry is in the same range as XOMA (83). This means that AVIR’s stock grew similarly to XOMA’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as XOMA (100). This means that AVIR’s stock grew similarly to XOMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRXOMA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
80%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIVCX13.08N/A
N/A
Allspring Special Large Cap Value C
HISCX25.83N/A
N/A
Hartford Small Cap Growth HLS IA
TMPIX53.62N/A
N/A
Touchstone Mid Cap Institutional
SAPEX17.80N/A
N/A
Spectrum Active Advantage Investor
TNVIX16.42N/A
N/A
1290 GAMCO Small/Mid Cap Value I